<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02115360</url>
  </required_header>
  <id_info>
    <org_study_id>2308/1/14</org_study_id>
    <nct_id>NCT02115360</nct_id>
  </id_info>
  <brief_title>Epidural Calcitonin in Lower Limb Amputation</brief_title>
  <official_title>The Pre-emptive Value of Epidural Calcitonin in Patients With Lower Limb Amputation. A Double Blinded Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <authority>Egypt: Ministry of Higher Education</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized double-blind clinical trial design will be used in a cohort of
      sixty patients of both genders, physical status American Society of Anaesthesiologist (ASA)
      I and II who will undergo  lower limb amputation, will be enrolled into the present study.
      Patients will divided randomly into two equal groups:  Epidural Bupivacain-Calcitonin and
      fentanyl (BC) Group and Bupivacain- fentanyl (BF) Group, comprising of 30 patients each.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>visual analogue scale</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary outcome of the study the analgesic effects of epidural calcitonin versus opioids administered for patients undergoing lower limb amputation surgery on postoperative pain using combined spinal epidural anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary outcome of this study is  to measure analgesic  consumption in patients undergoing lower limb amputation using combined spinal epidural anesthesia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>post amputation pain</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the development of post amputation phantom limb pain in calcitonin versus opioids administered for patients undergoing lower limb amputation surgery on postoperative pain using combined spinal epidural anesthesia.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amputation</condition>
  <condition>Partial Removal of Lower Limb</condition>
  <condition>Total Removal of Lower Limb</condition>
  <arm_group>
    <arm_group_label>Calcitonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle.  A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be  given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine,  100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle.  A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be  given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine,  100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin</intervention_name>
    <description>Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle.  A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be  given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine,  100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.</description>
    <arm_group_label>Calcitonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle.  A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be  given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine,  100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.</description>
    <arm_group_label>fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prospective randomized double-blind clinical trial design will be used in a cohort of
             sixty patients of both genders

          -  physical status American Society of Anaesthesiologist (ASA) I and II

          -  will undergo  lower limb amputation

        Exclusion Criteria:

          -  history of pituitary gland dysfunction

          -  cardiac disease

          -  chronic obstructive respiratory disease

          -  contraindications to performing an  epidural block such as:

               -  coagulation abnormalities

               -  spinal deformities, and

          -  patients allergic to local anesthetics and or calcitonin will be excluded from the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman A Yousef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman A Yousef, MD</last_name>
    <phone>00201003497767</phone>
    <email>ayman.yousef@rocketmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <state>Algharbyia</state>
        <zip>35217</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman A Yousef, MD</last_name>
      <phone>001003497767</phone>
      <email>ayman.yousef@rocketmail.com</email>
    </contact>
    <investigator>
      <last_name>Ayman A Yousef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int. 2012 Jan;23(1):17-38. doi: 10.1007/s00198-011-1676-0. Epub 2011 Jun 10. Review.</citation>
    <PMID>21660557</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman Abd Al-maksoud Yousef</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>epidural calcitonin</keyword>
  <keyword>amputation</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>Later Complication</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
